Abstract: The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.
Abstract: Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder.
Abstract: Compositions comprising hydroxytyrosol-containing formulations and treatment regiments comprising hydroxytyrosol and/or oleuropein and chemotherapeutic agents are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, such as a malignancy, and for inducing or enhancing angiogenesis, treating or preventing oxidative stress, for treating or preventing high glucose-induced dysfunction, treating or preventing chemotherapy-induced dysfunction, and for improving cell viability are provided. Various methods for use of the hydroxytyrosol compositions for inhibition of lysine specific demethylase 1 (LSD1) in various cancers are also provided.
Abstract: Methods for modulating inflammation using progesterone metabolites are disclosed. More particularly, methods of administering progesterone metabolites, 6?-hydroxyprogesterone (6?-OHP) and 16?-hydroxyprogesterone (16?-OHP) are disclosed for mitigating inflammation in various tissue types in the body.
Type:
Grant
Filed:
August 5, 2016
Date of Patent:
March 19, 2019
Assignee:
Indiana University Research and Technology Corporation
Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
Type:
Grant
Filed:
June 25, 2015
Date of Patent:
March 5, 2019
Assignee:
RHIZEN PHARMACEUTICALS SA
Inventors:
Dhanapalan Nagarathnam, Swaroop K. Vakkalanka, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Prashant K. Bhavar
Abstract: The present disclosure provides biophotonic compositions and methods useful in phototherapy. In particular, the biophotonic compositions of the present disclosure comprise at least two xanthene dyes. The biophotonic compositions and the method of the disclosure are useful for promoting wound healing and skin rejuvenation, as well as treating acne and other skin conditions.
Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent obesity.
Abstract: The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.
Abstract: Prenylated stilbene compounds and the use of such compounds in the treatment of diseases and medical disorders, for example cancer, skin ageing, inflammation, bacterial or fungal infection and immunosuppression.
Type:
Grant
Filed:
May 4, 2012
Date of Patent:
February 5, 2019
Assignee:
The University of Sydney
Inventors:
Colin Charles Duke, Van Hoan Tran, Rujee Kyokajee Duke
Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, Q, U, W, Z, X and Y are as described herein, compositions including the compounds and methods of using the compounds. These compounds are HbsAg inhibitors and are useful as medicaments for the treatment or prophylaxis of HBV infection.
Abstract: The invention relates to the use of an inhibitor of the dihydrofolate reductase enzyme selected from the group that consists of methotrexate, trimetrexate and pemetrexed; or a pharmaceutically acceptable salt thereof, for the preparation of a drug for the treatment or prevention of recurrences of a disease selected from the group that consists of cancer, psoriasis, psoriatic arthritis, juvenile polyarticular arthritis, rheumatoid arthritis, Crohn's disease, polymyositis, dermatomyositis and sarcoidosis, wherein said treatment or prevention includes administering to a patient, simultaneously, separately or sequentially, a lipophilic statin and the inhibitor of the dihydrofolate reductase enzyme. The invention also relates to a pharmaceutical composition which includes the inhibitor of the dihydrofolate reductase enzyme and the lipophilic statin together with pharmaceutically acceptable carriers and/or vehicles.
Abstract: Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from when, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH.
Abstract: The present invention provides compounds and compositions for the amelioration of arthritis and joint injuries by inducing mesenchymal stem cells into chondrocytes.
Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
Type:
Grant
Filed:
December 23, 2015
Date of Patent:
January 1, 2019
Assignee:
Amarin Pharmaceuticals Ireland Limited
Inventors:
Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski
Abstract: A method of preventing or reducing the occurrence of malondiadehyde and/or levuglandin protein modification in a subject in need thereof, comprising administering to said subject an effective amount of at least one ?-KA scavenger compound, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
December 21, 2016
Date of Patent:
January 1, 2019
Assignee:
Vanderbilt University
Inventors:
John A. Oates, Olivier Boutaud, Irene Zagol-Ikapitte
Abstract: The present invention improves the solubility of sesamin-class compounds in fish oil and/or wheat germ oil. More specifically, ?-orizanol is combined with fish oil and/or wheat germ oil as well as sesamin-class compounds.
Abstract: The present invention relates to cancer markers that are predictive for cancer patent response to treatment with an m TOR inhibitor and a vascular disrupting agent. The present invention further relates to methods of treating a cancer patient subpopulation with a combination of an m TOR inhibitor and a vascular disrupting agent.
Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.
Type:
Grant
Filed:
May 5, 2015
Date of Patent:
December 18, 2018
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Thomas J. Slaga, Jacob Junco, Huiyun Liang, Sara Reyna
Abstract: Bismuth-containing compounds include bismuth and a biologically active agent coordinated to the bismuth. The biologically active agent includes at least one heteroatom configured for coordination with the bismuth. Coordination polymers include a polymer matrix that contains a bismuth-containing compound. Methods for modulating a pharmacokinetic property of a biologically active agent include coordinating the biologically active agent to bismuth to form a bismuth-containing compound, and administering the bismuth-containing compound orally to a patient. Methods for treating Parkinson's disease, methods for treating hypothyroidism, methods for treating ulcerative colitis, and methods for treating cancer each include administering a bismuth-containing compound to a patient.
Type:
Grant
Filed:
November 8, 2010
Date of Patent:
December 11, 2018
Assignee:
Synthonics, Inc.
Inventors:
John D. Price, Thomas Piccariello, Robert A. Oberlender, Michaela E. Mulhare, Scott B. Palmer
Abstract: A mineral-vitamin complex for osteoporosis includes at least 92 mass % of the mineral-vitamin complex of amino acids and Krebs cycle acids and/or Krebs cycle acid salts, wherein the amino acids include glycine of between 1% and 80% of the mineral-vitamin complex, and wherein the Krebs cycle acids and/or Krebs cycle acid salts are up to 5 mass % of the mineral-vitamin complex; and valine, leucine and isoleucine such that a mass ratio of glycine to a sum of valine+leucine+isoleucine is in a range of 10-1000. Optionally, the valine, leucine and isoleucine are derived from dry milk, any stable dry product derived from milk and/or a mix thereof. Optionally, the following compounds are used as a source of Krebs cycle acid salts: Y-Me-Y.nH2O, where Me—divalent metal, from Ca, Mg, Zn group, Y—anion of an acid participating in Krebs cycle, and n=0-12.
Type:
Grant
Filed:
June 8, 2017
Date of Patent:
November 20, 2018
Inventors:
Mikhail Lvovich Uchitel, Roman Anatolievich Trunin, Evgenij Iljich Maevskij